Sacituzumab and bevacizumab for platinum-resistant ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests two targeted drugs — sacituzumab tirumotecan (which attacks cancer cells) and bevacizumab (which cuts off blood supply to tumors) — for ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination helps shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and at least 18 years old.
- You have ovarian cancer (or related cancer of the peritoneum or fallopian tube) that came back within 6 months after your last platinum chemotherapy (like carboplatin or cisplatin).
- You have had 1 to 3 previous treatments for your cancer (these may have included bevacizumab or PARP inhibitors).
- You feel well enough to do light housework or more (ECOG 0-1).
- Your cancer has not spread to the brain, or if it has, the brain spots are not causing symptoms or are stable.
- You have not had surgery or other cancer therapy that you haven't recovered from, and you have no serious heart, liver, kidney, or other health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug combination (sacituzumab govitecan plus bevacizumab) works better than the usual chemotherapy for ovarian cancer that has come back after platinum treatment and PARP inhibitor maintenance. It may offer a new option for people with certain genetic markers (BRCA mutations or HRD).
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
This trial tests whether taking two drugs, senaparib and bevacizumab, after initial chemotherapy can help keep advanced ovarian cancer from coming back. It is for patients whose tumors are homologous recombination proficient (HRP), meaning their cancer cells are better at repairing DNA, and who have responded well to their first platinum-based treatment.
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
Hear when a new Platinum-resistant Recurrent Ovarian Cancer (PROC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.